DDB1 and CUL4 associated factor 1Genealiases: RIP · VPRBP
Q-omics provides the consensus-scored DCAF1 profile across patient tissues and cancer cell-line models. DCAF1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, DCAF1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, DCAF1 RNA expression shows 20,595 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, COAD, and ACC as cancer lineages where DCAF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF1 survival associations across molecular data types. DCAF1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF1 RNA expression–survival associations across cancer types. High DCAF1 expression shows favorable associations in SCLC, KIRC, UCS, BRCA, READ and THYM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for DCAF1 RNA expression.
This table summarizes DCAF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DCAF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF1 shows lower tumor expression in KIRC and THCA and higher tumor expression in COAD, STAD, LIHC and BLCA. The COAD box plot shows higher DCAF1 RNA expression in tumor versus normal tissue (log2 FC = +0.709, t-test p < 0.001).
This table shows molecular features associated with DCAF1 in patient tissues and cancer cell lines. In patient samples, DCAF1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
